Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Retinal surgeons are buzzing about the latest vitreoretinal surgical platforms, with Alcon's Unity system leading the conversation. Experts from top institutions shared their experiences with Unity, DORC Eva Nexus, and Stellaris Elite, praising advances in fluidics, laser technology, and dual cataract-retinal functionality. Budget constraints and device life cycles, however, remain real barriers to upgrading.
A panel of leading vitreoretinal surgeons, convened by Healio's OSN Retina/Vitreous Board, weighed in on the newest generation of surgical platforms — and the practical hurdles of getting them into operating rooms. Alcon's Unity system drew the most attention, with surgeons highlighting its flow-based fluidics, 30,000 cuts-per-minute vitrectomy speed, and TetraSpot multi-spot laser as meaningful upgrades for efficiency and precision — particularly when treating complex conditions like proliferative diabetic retinopathy or working with trainees.
Beyond Unity, the panel also spotlighted the DORC Eva Nexus (Zeiss) and Bausch + Lomb's Stellaris Elite as strong alternatives, each with distinct advantages in footprint, fluidics, and phaco compatibility. BVI's Virtuoso, though not yet FDA-cleared, earned a mention after its CE-marked European debut. The consensus: all current platforms are solid, and choice largely comes down to personal preference and institutional fit.
Key Takeaways:
Why it matters: As vitreoretinal surgery grows more complex, the tools surgeons use directly impact patient outcomes and training quality. Understanding the strengths and trade-offs of each platform helps institutions make smarter, longer-lasting investment decisions.